Niklas LindegardhWarunee HanpithakpongBenjamas KamanikomJeremy FarrarTran Tinh HienPratap SinghasivanonNicholas J. WhiteNicholas P J DayMahidol UniversityNuffield Department of Clinical MedicineUCL2018-05-032018-05-032011-01-01Bioanalysis. Vol.3, No.2 (2011), 157-16517576199175761802-s2.0-79951925101https://repository.li.mahidol.ac.th/handle/20.500.14594/11635Background: Parenteral zanamivir is a promising drug for the treatment of severe influenza. However, quantification of this polar drug in biological matrices has traditionally been difficult and the methods developed have been relatively insensitive. Results: A high-throughput bioanalytical method for the analysis of zanamivir in human plasma using SPE in the 96-well plate format and LC coupled to positive MS/MS has been developed and validated according to US FDA guidelines. The method uses 50 Âμ l of plasma and covers a large working range from 1-50, 000 ng/ml with a LOD of 0.50 ng/ml. Conclusion: This new LC-MS/MS assay is more sensitive than previous methods despite using a small plasma volume sample. It is particularly suitable for clinical studies on both parenteral and inhaled zanamivir. © 2011 Future Science Ltd.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyChemistryHealth ProfessionsPharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.4155/bio.10.189